|
1
|
Jemal A, Siegel R, Xu J and Ward E: Cancer
statistics, 2010. CA Cancer J Clin. 60:277–300. 2010.
|
|
2
|
Stein U and Schlag PM: Clinical,
biological, and molecular aspects of metastasis in colorectal
cancer. Recent Results Cancer Res. 176:61–80. 2007.
|
|
3
|
Birchmeier C, Birchmeier W, Gherardi E and
Vande Woude GF: Met, metastasis, motility and more. Nat Rev Mol
Cell Biol. 4:915–925. 2003.
|
|
4
|
Mazzone M and Comoglio PM: The Met
pathway: master switch and drug target in cancer progression. FASEB
J. 20:1611–1621. 2006.
|
|
5
|
Sattler M and Salgia R: c-Met and
hepatocyte growth factor: potential as novel targets in cancer
therapy. Curr Oncol Rep. 9:102–108. 2007.
|
|
6
|
Potempa S and Ridley AJ: Activation of
both MAP kinase and phosphatidylinositide 3-kinase by Ras is
required for hepatocyte growth factor/scatter factor-induced
adherens junction disassembly. Mol Biol Cell. 9:2185–2200.
1998.
|
|
7
|
Watanabe T, Itabashi M, Shimada Y, et al:
Japanese Society for Cancer of the Colon and Rectum: Japanese
Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2010
for the treatment of colorectal cancer. Int J Clin Oncol. 17:1–29.
2012.
|
|
8
|
Sobin LH and Fleming ID: TNM
classification of malignant tumors, fifth edition (1997). Union
Internationale Contre le Cancer and the American Joint Committee on
Cancer. Cancer. 80:1803–1804. 1997.
|
|
9
|
Mimori K, Mori M, Shiraishi T, et al:
Clinical significance of tissue inhibitor of metalloproteinase
expression in gastric carcinoma. Br J Cancer. 76:531–536. 1997.
|
|
10
|
Mori M, Staniunas RJ, Barnard GF, et al:
The significance of carbonic anhydrase expression in human
colorectal cancer. Gastroenterology. 105:820–826. 1993.
|
|
11
|
Stein U: MACC1-a novel target for solid
cancers. Expert Opin Ther Targets. 17:1039–1052. 2013.
|
|
12
|
Stein U, Walther W, Arlt F, et al: MACC1,
a newly identified key regulator of HGF-MET signaling, predicts
colon cancer metastasis. Nat Med. 15:59–67. 2009.
|
|
13
|
André T, Quinaux E, Louvet C, et al: Phase
III study comparing a semimonthly with a monthly regimen of
fluorouracil and leucovorin as adjuvant treatment for stage II and
III colon cancer patients: final results of GERCOR C96.1. J Clin
Oncol. 25:3732–3738. 2007.
|
|
14
|
Juneja M, Ilm K, Schlag PM and Stein U:
Promoter identification and transcriptional regulation of the
metastasis gene MACC1 in colorectal cancer. Mol Oncol. 7:929–943.
2013.
|
|
15
|
Zhang Y, Wang Z, Chen M, et al:
MicroRNA-143 targets MACC1 to inhibit cell invasion and migration
in colorectal cancer. Mol Cancer. 11:232012.
|
|
16
|
Wolpin BM and Mayer RJ: Systemic treatment
of colorectal cancer. Gastroenterology. 134:1296–1310. 2008.
|
|
17
|
Kornmann M, Formentini A, Ette C, et al:
Prognostic factors influencing the survival of patients with colon
cancer receiving adjuvant 5-FU treatment. Eur J Surg Oncol.
34:1316–1321. 2008.
|
|
18
|
Bathe OF, Dowden S, Sutherland F, et al:
Phase II study of neoadjuvant 5-FU + leucovorin + CPT-11 in
patients with resectable liver metastases from colorectal
adenocarcinoma. BMC Cancer. 4:322004.
|
|
19
|
Sadanandam A, Lyssiotis CA, Homicsko K, et
al: A colorectal cancer classification system that associates
cellular phenotype and responses to therapy. Nat Med. 19:619–625.
2013.
|
|
20
|
Iijima M, Kano Y, Nohno T and Namba M:
Cloning of cDNA with possible transcription factor activity at the
G1-S phase transition in human fibroblast cell lines. Acta Med
Okayama. 50:73–77. 1996.
|
|
21
|
Hansen WJ, Cowan NJ and Welch WJ:
Prefoldin-nascent chain complexes in the folding of cytoskeletal
proteins. J Cell Biol. 145:265–277. 1999.
|
|
22
|
Hodgson G, Hager JH, Volik S, et al:
Genome scanning with array CGH delineates regional alterations in
mouse islet carcinomas. Nat Genet. 29:459–464. 2001.
|
|
23
|
Lacy AM, García-Valdecasas JC, Delgado S,
et al: Laparoscopy-assisted colectomy versus open colectomy for
treatment of non-metastatic colon cancer: a randomised trial.
Lancet. 359:2224–2229. 2002.
|
|
24
|
Weeks JC, Nelson H, Gelber S, et al:
Short-term quality-of-life outcomes following laparoscopic-assisted
colectomy vs open colectomy for colon cancer: a randomized trial.
JAMA. 287:321–328. 2002.
|
|
25
|
No authors listed. Laparoscopically
assisted colectomy is as safe and effective as open colectomy in
people with colon cancer Abstracted from: Nelson H, Sargent D,
Wieand HS, et al: for the Clinical Outcomes of Surgical Therapy
Study Group. A comparison of laparoscopically assisted and open
colectomy for colon cancer. N Engl J Med. 350:2050–2059. 2004.
|
|
26
|
Jayne DG, Guillou PJ, Thorpe H, et al; UK
MRC CLASICC Trial Group. Randomized trial of laparoscopic-assisted
resection of colorectal carcinoma: 3-year results of the UK MRC
CLASICC Trial Group. J Clin Oncol. 25:3061–3068. 2007.
|
|
27
|
Koshariya M, Jagad RB, Kawamoto J, et al:
An update and our experience with metastatic liver disease.
Hepatogastroenterology. 54:2232–2239. 2007.
|
